Skip to content

Role of Dietary Fatty Acids in Fatty Liver and Insulin Resistance

Role of Dietary Fatty Acids in Fatty Liver and Insulin Resistance: a Randomized Controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01038102
Acronym
HEPFAT
Enrollment
65
Registered
2009-12-23
Start date
2009-02-28
Completion date
2010-04-30
Last updated
2010-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Fatty Liver, Insulin Resistance, Obesity

Keywords

Obesity, Diabetes, Insulin resistance, Fatty liver, NAFLD, Steatosis, Dietary fatty acids

Brief summary

The purpose of this study is to investigate whether substituting saturated fats with polyunsaturated fats reduces fatty liver and improves insulin action and other metabolic variables in abdominally obese subjects

Detailed description

Specific goals: 1. Investigate if substituting saturated fats with polyunsaturated fats reduces steatosis and improves hepatic and/or peripheral insulin action in abdominally obese subjects with type 2 diabetes 2. Investigate if changes of lipogenic enzymes in response to dietary fat intervention are associated with changes in hepatic/peripheral insulin sensitivity or liver fat content 3. Investigate potential mechanism of the effects of dietary fatty acids; e.g. gene expression and lipogenic enzyme activity

Interventions

Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%).

Diet high in saturated fat (15E%)

Sponsors

Swedish Council for Working Life and Social Research
CollaboratorOTHER
Uppsala University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* abdominal obese subjects with or without type 2 diabetes * sagittal abdominal diameter \>25cm

Exclusion criteria

* insulin treatment * history of serious cardiovascular events * morbid obesity * claustrophobia (relative criterion)

Design outcomes

Primary

MeasureTime frame
Hepatic steatosis by MRT10 weeks

Secondary

MeasureTime frame
Insulin resistance by oral glucose tolerance test10 weeks
Changes in adipose tissue gene expression and lipogenic enzyme activity10 weeks

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026